Allium Medical Receives a Janapese Patent for TPS

Allium Medical Solutions Ltd., the developer and manufacturer of innovative, site-specific stents for the urinary, biliary and gastro-intestinal systems, announced that it has been granted a patent by the Japanese Patent Office for its application named "STENT". The filing refers to the unique design of its Triangular Prostatic Stent (TPS). The TPS is a novel solution for patients for the management of posterior urethral occlusions caused by benign and malignant prostatic enlargements,. The TPS has a large caliber triangular cross-section to match the contours of the prostatic urethral lumen and the ability to exert varying degrees of radial force depending on the anatomy. These unique characteristics allow for excellent flow and improved comfort compared to existing stents, without jeopardizing the male's voluntary continence mechanism. The TPS helps treat Benign Prostate Hyperplasia (BPH) patients, which according to the AJMC, is one of the most common diseases of aging men, ranking in the top 10 most commonly diagnosed conditions in men over age 50 years. The National Institutes of Health (NIH) states that BPH affects more than 50% of men over age 60 and as many as 90% of men over the age of 70.

The "STENT" patent in Japan has been followed by approval of the "STENT" patent in Europe in December of 2010. Allium's CEO Ronen Castro states, "We are pleased about both patent approvals because they strengthen Allium's ability to present to our customers and users the clinical advantages for our products".
Allium was recently announced as a winner of the prestigious 2011 Medical Design Excellence Awards competition for its TPS. The competition is a premier awards program for the medical community and is organized and presented by UBM Canon, which recognizes the achievements of medical product manufacturers and the many people behind the scenes who are responsible for creating innovative products that are changing the face of healthcare.

Founded in 2001, Allium Medical is a publicly traded company in the Tel Aviv Stock Exchange (TASE). Its products are based on a proprietary technology originated by Prof. (Em) Daniel Yachia, a world-renowned expert in the field of urological stents and the founder of the company. Allium develops, manufactures and markets its peripheral stents from its premises in Caesarea, Israel. With a mission to address the unmet needs and common problems in non-vascular peripheral stents, the company has developed an advanced technological platform and manufacturing processes for its stenting solutions. Allium stents are self-expandable, flexible and fully covered, made of a thin polymeric layer built on a skeleton of nitinol to prevent tissue ingrowth into the lumen as well as incrustation, both common problems with metal stents. The stents are designed for a long indwelling periods, provide safe and effective anchoring to prevent migration, are easily and safely removed by the unique, unraveling mechanism. Allium stents are distributed throughout most European countries and are CE approved.

Allium Medical Solutions Ltd.
2 Ha'Eshel St. Caesarea, Israel 38900
Ms. Tali Tamir Gal - Insides Sales and Marketing Specialist

This release was published on openPR.